NeoVirTech SAS opens a new laboratory at the Cancerology Research Center of Toulouse (CRCT) to structure its anticancer programs towards the creation of a patient- driven theragnostic platform and to foster drug development.
NeoVirTech provides access to its ANCHORTM technology platform to develop disruptive models for the investigation of cancer-associated mechanisms and the preclinical development of oncolytic virotherapies.
More specifically, NeoVirTech and CRCT Team 10 aim to develop a rapid and reliable theranostic platform to ensure the efficacy of oncolytic virotherapies in cancer patients.
Long-term collaboration will ensure patient benefits and reduce the time to decision for individualised cancer therapies.